新型冠状病毒肺炎、血管紧张素转换酶2和血压管理

COVID-19,Angiotensin-converting enzyme 2 and blood pressure management

本次严重威胁公共卫生安全的新型冠状病毒与严重急性呼吸综合征冠状病毒(SARS-CoV)的基因特征高度相似。血管紧张素转化酶2(ACE2)是肾素-血管紧张素系统(RAS)的重要组成部分,在新型冠状病毒对呼吸系统的影响中起双重作用。ACE2介导血管紧张素Ⅱ(Ang Ⅱ)水解,生成血管紧张素1-7作用于Mas受体,保护肺组织。另一方面,新型冠状病毒通过Spike蛋白与肺组织ACE2感染人体,是导致新型冠状病毒肺炎(COVID-19)的主要途径。降血压药物,尤其是RAS抑制剂对人体肺组织ACE2的影响目前尚不明确。对于COVID-19患者,目前尚无证据表明服用RAS抑制剂会增加病毒感染机会或加重感染,不建议擅自调整或停用降血压药物。

The novel coronavirus(2019-nCoV),which genetic characteristics is highly similar to the severe acute respiratory syndrome coronavirus(SARS-CoV),seriously threatens public health and safety.Angiotensin-converting enzyme 2(ACE2),an important component of renin-angiotension system(RAS),plays a dual role in the effects of 2019-nCoV on the respiratory system.ACE2 mediates the hydrolysis of Ang Ⅱ to ang 1-7,which acts on Mas receptor and protects lung tissues.The combination of Spike protein and(ACE2)is the main route of novel coronavirus pneumonia(COVID-19)infection.The effect of antihypertensive drugs,especially RAS inhibitors,on ACE2 of human lung is not clear.For COVID-19 patients,there is no evidence that taking RAS inhibitor will increase the risk of virus infection or aggravate the infection.It is not recommended to adjust or stop the antihypertensive drugs without authorization.